
Quarterly report 2025-Q3
added 11-03-2025
Castle Biosciences Net Debt 2011-2025 | CSTL
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Castle Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -108 M | -97.7 M | -121 M | -328 M | -410 M | -73.7 M | 20 M | 17.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 20 M | -410 M | -138 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 19.29 | -1.73 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 21.26 | -2.34 % | $ 229 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
-11.2 M | - | -13.05 % | $ 7.29 M | ||
|
Danaher Corporation
DHR
|
13.6 B | $ 231.47 | 0.28 % | $ 169 B | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.04 | -0.99 % | $ 285 M | ||
|
DexCom
DXCM
|
-487 M | $ 67.42 | 0.84 % | $ 26 B | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.52 | -0.65 % | $ 1.93 M | ||
|
Exact Sciences Corporation
EXAS
|
-560 M | $ 101.54 | -0.05 % | $ 18.8 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 27.01 | -0.55 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 19.73 | -1.45 % | $ 1.06 B | ||
|
Celcuity
CELC
|
82.8 M | $ 102.61 | 0.25 % | $ 4.05 B | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.42 | 3.64 % | $ 109 K | ||
|
Co-Diagnostics
CODX
|
-11.9 M | $ 0.24 | -1.79 % | $ 7.04 M | ||
|
IQVIA Holdings
IQV
|
11.2 B | $ 226.02 | 0.39 % | $ 41 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Guardant Health
GH
|
646 M | $ 102.38 | -0.12 % | $ 12.6 B | ||
|
NeoGenomics
NEO
|
-23.3 M | $ 12.3 | -0.97 % | $ 1.56 B | ||
|
Neogen Corporation
NEOG
|
751 M | $ 7.14 | -0.14 % | $ 1.55 B | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
National Research Corporation
NRC
|
30.1 M | $ 18.81 | -1.05 % | $ 462 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
Organovo Holdings
ONVO
|
-10.4 M | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
711 K | - | -16.95 % | $ 1.54 M | ||
|
OPKO Health
OPK
|
-411 M | $ 1.3 | -0.76 % | $ 902 M | ||
|
Mettler-Toledo International
MTD
|
1.8 B | $ 1 417.16 | 0.18 % | $ 30.1 B | ||
|
Illumina
ILMN
|
-494 M | $ 135.32 | -0.64 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
2.1 B | $ 203.16 | 0.14 % | $ 10.4 B | ||
|
ENDRA Life Sciences
NDRA
|
-4.37 M | $ 5.1 | - | $ 2.74 M | ||
|
Pacific Biosciences of California
PACB
|
-139 M | $ 1.88 | 3.3 % | $ 477 M | ||
|
PerkinElmer
PKI
|
1.99 B | - | -0.91 % | $ 14.7 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 175.92 | 0.48 % | $ 19.5 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 6.82 | 1.04 % | $ 884 M | ||
|
Myriad Genetics
MYGN
|
115 M | $ 6.55 | -0.15 % | $ 593 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4 B | $ 254.46 | 0.52 % | $ 21.3 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 183.68 | 0.33 % | $ 15.2 B | ||
|
IDEXX Laboratories
IDXX
|
183 M | $ 688.18 | 0.86 % | $ 56.8 B |